Sapropterin dihydrochloride + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Phenylketonuria
Conditions
Phenylketonuria
Trial Timeline
Aug 1, 2010 → Mar 1, 2013
NCT ID
NCT01114737About Sapropterin dihydrochloride + Placebo
Sapropterin dihydrochloride + Placebo is a phase 3 stage product being developed by BioMarin Pharmaceutical for Phenylketonuria. The current trial status is completed. This product is registered under clinical trial identifier NCT01114737. Target conditions include Phenylketonuria.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01114737 | Phase 3 | Completed |
| NCT00272792 | Phase 3 | Completed |
Competing Products
20 competing products in Phenylketonuria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SYNB1934v1 + Placebo | Synlogic | Phase 3 | 69 |
| SYNB1618 + Placebo | Synlogic | Phase 1/2 | 33 |
| SYNB1618 + SYNB1934 | Synlogic | Phase 2 | 44 |
| Kuvan® | Merck | Phase 3 | 77 |
| Kuvan® | Merck | Approved | 85 |
| SAR444836 | Sanofi | Phase 1/2 | 40 |
| Kuvan | BioMarin Pharmaceutical | Pre-clinical | 20 |
| rAvPAL-PEG | BioMarin Pharmaceutical | Phase 2 | 49 |
| rAvPAL-PEG | BioMarin Pharmaceutical | Phase 2 | 49 |
| Sapropterin (Kuvan) | BioMarin Pharmaceutical | Pre-clinical | 20 |
| BMN 165 (rAvPAL-PEG) | BioMarin Pharmaceutical | Phase 2 | 49 |
| BMN 307 | BioMarin Pharmaceutical | Phase 1/2 | 38 |
| Sapropterin | BioMarin Pharmaceutical | Pre-clinical | 20 |
| BMN165 20mg/day + BMN165 40mg/day + Placebo | BioMarin Pharmaceutical | Phase 3 | 74 |
| sapropterin dihydrochloride | BioMarin Pharmaceutical | Phase 3 | 74 |
| saproterin dihydrochloride | BioMarin Pharmaceutical | Approved | 82 |
| sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placebo | BioMarin Pharmaceutical | Phase 1 | 30 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 20 |
| sapropterin dihydrochloride | BioMarin Pharmaceutical | Phase 2 | 49 |